Most Recent
The ACCC has flagged competition concerns about drug supplier Sigma Healthcare's proposed $8.8 billion reverse merger with Chemist Warehouse, saying the tie-up could harm independent pharmacies and lessen competition in pharmacy retail.
The Mining and Energy Union is pursuing pay increases of up to $40,000 per year for labour hire workers at three BHP coal mines under new legislation, saying the energy giant's use of labour hire to cut pay was "out of step" with community standards and the law.
Four judges made this year's King’s Birthday Honours list for their service to the law and the judiciary.
A day after the National Anti-Corruption Commission closed its investigation of six officials linked to the Robodebt scandal, an appeals court has overturned a decision barring access by a campaigner to documents related to the disastrous scheme for collecting Centrelink debts.
A judge has ordered SkyCity to pay a $67 million penalty in AUSTRAC’s case alleging it allowed $4 billion in suspicious transactions, finding it was an "appropriate" sum, even when compared with the $450 million fine handed to Crown last July.
The Iconic has defeated a challenge to the online fashion retailer's application to trade mark ‘Considered’ for sustainable or ethically sourced products, with IP Australia rejecting Net-a-Porter's argument that the label has not been used in the sense required under the Trade Marks Act.
The Fair Work Commission has found a former PricewaterhouseCoopers director should not have relied solely on a colleague's text message in deciding to resign while on leave, rejecting her argument that the accounting firm had essentially forced her resignation.
The Australian Council of Trade Unions is planning to challenge junior pay rates at the Fair Work Commission, arguing that the deck is unfairly stacked against young people.
Litigation hobbyist Clive Palmer has filed proceedings against former Australian Securities and Investments Commission chair James Shipton, alleging he acted in bad faith and beyond his power in the regulator's pursuit of claims against him.
Drug giant Pfizer has blasted Samsung Bioepis' “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.